Welcome to our dedicated page for FINCH THERAPEUTCS GRP news (Ticker: FNCH), a resource for investors and traders seeking the latest updates and insights on FINCH THERAPEUTCS GRP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FINCH THERAPEUTCS GRP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FINCH THERAPEUTCS GRP's position in the market.
Finch Therapeutics Group, Inc. (Nasdaq: FNCH) announced positive results from the PRISM3 Phase 2 trial for its investigational microbiome therapeutic, CP101, aimed at preventing recurrent C. difficile infection. The data revealed a statistically significant efficacy, showing a 73.5% sustained clinical cure rate at 24 weeks for CP101 compared to 59.4% for placebo (p=0.0347). Notably, CP101 maintained a favorable safety profile with no severe drug-related adverse events. These findings support CP101's potential as a first-line treatment option for recurrent CDI, paving the way for further development in upcoming trials.
Finch Therapeutics Group (Nasdaq: FNCH) announced that CEO Mark Smith, PhD, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021. The presentation is pre-recorded and will be available at 4:45 pm ET on Finch's website, archived for 30 days. Finch is a clinical-stage microbiome therapeutics company focused on developing innovative orally administered drugs. Its lead candidate, CP101, targets recurrent C. difficile infections and has received FDA Breakthrough Therapy and Fast Track designations.
Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has announced the appointment of Samuel Allen Hamood to its Board of Directors. With over 30 years of experience in finance, M&A, and corporate strategy, Hamood brings a wealth of expertise. He is currently the President and CFO of Culligan International and has held leadership positions at ATI Physical Therapy and Change Healthcare. Hamood expressed enthusiasm for Finch's progress in microbiome therapeutics, particularly the CP101 program aimed at recurrent C. difficile infection, highlighting near-term clinical milestones.
Finch Therapeutics (Nasdaq: FNCH) announced the appointment of Marc Blaustein as Chief Operating Officer, bringing over 20 years of biopharmaceutical experience. CEO Mark Smith highlighted Blaustein's proven track record in drug development as vital for Finch's growth phase, especially with the lead candidate, CP101, in late-stage clinical development for C. difficile infection. Blaustein previously held key roles at various biotechnology firms and is expected to enhance Finch's momentum in microbiome therapeutics.
SOMERVILLE, Mass., Sept. 07, 2021 – Finch Therapeutics Group (Nasdaq: FNCH) announced that CEO Mark Smith, PhD, will present an overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The on-demand presentation will be accessible on September 13 at 7:00 am ET on Finch's website. Finch Therapeutics specializes in microbiome therapeutics and has a pipeline including CP101, which targets recurrent C. difficile infections and has received FDA Breakthrough Therapy designation.
Finch Therapeutics (Nasdaq: FNCH) reported a net loss of $15.2 million for Q2 2021, up from $8.3 million in Q2 2020, mainly due to increased research and development costs. R&D expenses rose to $14.0 million from $8.1 million, reflecting personnel and manufacturing costs. The company is advancing its clinical programs, with significant data readouts anticipated in 2022, including trials for CP101 in recurrent CDI and chronic HBV. Finch's cash reserves totaled $168.1 million, expected to support operations into mid-2023.
Finch Therapeutics (Nasdaq: FNCH) announced the transition of its FIN-524 program for ulcerative colitis to Takeda, which will now lead clinical development as TAK-524. This partnership aims to utilize Takeda’s expertise in inflammatory bowel disease (IBD), enhancing the potential for successful therapy. Since 2017, Finch has received $10 million upfront and $4 million in milestones, with the possibility of an additional $176 million tied to future milestones. The FIN-524 product candidate aims to modulate the gut microbiome to treat ulcerative colitis, a significant autoimmune condition affecting millions worldwide.
Finch Therapeutics Group, Inc. (Nasdaq: FNCH) announced its inclusion in the Russell 2000 and Russell 3000 Indexes effective June 25, 2021. This annual reconstitution recognizes the top 4,000 US stocks based on market capitalization, enhancing Finch's visibility in the investment community. The company is advancing its lead product candidate, CP101, for recurrent C. difficile infection, with Phase 3 trials planned. Finch also develops therapeutics for conditions like chronic hepatitis B and autism spectrum disorder.
Finch Therapeutics Group (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company, announced that CEO Mark Smith will participate in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:00 am ET, followed by the JMP Securities Life Sciences Conference on June 17, 2021, at 2:00 pm ET. Live webcasts of both events will be available on the Finch website, with replays accessible for 30 days. Finch is known for its innovative Human-First Discovery platform and the lead candidate CP101, aimed at treating recurrent C. difficile infections.
Finch Therapeutics Group (Nasdaq: FNCH) successfully completed an upsized IPO, raising approximately $130.8 million in gross proceeds. The company reported a net loss of $14.0 million for Q1 2021, a rise from $7.9 million in the same period last year, due to increased research and development expenses. Upcoming milestones include the initiation of Phase 3 trials for CP101 in recurrent C. difficile infection and Phase 1 trials for chronic hepatitis B and autism, with significant data expected in H2 2021 and 2022. Finch's cash position is strong, with $193.0 million in hand, sufficient to fund operations into mid-2023.
FAQ
What is the current stock price of FINCH THERAPEUTCS GRP (FNCH)?
What is the market cap of FINCH THERAPEUTCS GRP (FNCH)?
